Co-targeting RANK Pathway Treats and Prevents Acquired Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2023 Jul 14

PMID 37451269

Authors

Ines Gomes

Lina M Gallego-Paez

Maria Jimenez

Patricia G Santamaria

Andre Mansinho

Rita Sousa

Catarina Abreu

Eva Gonzalez Suarez

Luis Costa

Sandra Casimiro

Affiliations

Soon will be listed here.

Abstract

The combination of endocrine therapy (ET) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) was a hallmark in metastatic luminal breast cancer (BC). However, intrinsic and acquired resistance affects long-term efficacy. Here, we study the role of the receptor activator of nuclear factor-κB (RANK) pathway in CDK4/6i resistance. We find that RANK overexpression in luminal BC is associated with intrinsic resistance to CDK4/6i, both in vitro and in mouse xenografts, and decreased proliferation rate and chronic interferon (IFN) γ response are highlighted as resistance drivers. Gene expression data from the NeoPalAna CDK4/6i clinical trial, and studies with palbociclib-resistant cell lines, show that RANK is upregulated after treatment with CDK4/6i, supporting a role in acquired resistance. Our study shows that RANK ligand (RANKL) inhibitors can restore sensitivity to CDK4/6i and prevent acquired resistance. On the basis of these findings, we conclude that pharmacological inhibition of the RANK pathway through RANKL blocking could represent an add-on to ET + CDK4/6i, warranting further clinical studies.

Citing Articles

CDK14 regulates the development and repair of lung.

Chen J, Wang Y, Gao R, Ma L, Zhong J, Yang J Cell Death Discov. 2025; 11(1):12.

PMID: 39827158 PMC: 11743204. DOI: 10.1038/s41420-025-02292-4.

Downregulation of the splicing regulator NSRP1 confers resistance to CDK4/6 inhibitors via activation of interferon signaling in breast cancer.

Yu S, Si Y, Xu M, Wang Y, Liu C, Bi C J Biol Chem. 2024; 301(1):108070.

PMID: 39667501 PMC: 11750474. DOI: 10.1016/j.jbc.2024.108070.

Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy.

Akdag G, Dogan A, Yildirim S, Kinikoglu O, Mokresh M, Alomari O Cureus. 2024; 16(6):e63362.

PMID: 39070363 PMC: 11283752. DOI: 10.7759/cureus.63362.

Centrosomes and associated proteins in pathogenesis and treatment of breast cancer.

Athwal H, Kochiyanil A, Bhat V, Allan A, Parsyan A Front Oncol. 2024; 14:1370565.

PMID: 38606093 PMC: 11007099. DOI: 10.3389/fonc.2024.1370565.

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer.

Gomes I, Abreu C, Costa L, Casimiro S Cancers (Basel). 2023; 15(19).

PMID: 37835528 PMC: 10571967. DOI: 10.3390/cancers15194835.

References

Li Z, Zou W, Zhang J, Zhang Y, Xu Q, Li S . Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer. Front Pharmacol. 2020; 11:580251. PMC: 7751736. DOI: 10.3389/fphar.2020.580251. View

Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A . RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res. 2012; 72(11):2879-88. DOI: 10.1158/0008-5472.CAN-12-0044. View

Pellegrini P, Pasquale P, Cordero A, Alex C, Gallego M, Marta Ines G . Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells. 2013; 31(9):1954-65. DOI: 10.1002/stem.1454. View

Abe T, Sato T, Kokabu S, Hori N, Shimamura Y, Sato T . Zoledronic acid increases the circulating soluble RANKL level in mice, with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide. Cytokine. 2016; 83:1-7. DOI: 10.1016/j.cyto.2016.03.012. View

Li B, Dewey C . RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12:323. PMC: 3163565. DOI: 10.1186/1471-2105-12-323. View

Benci J, Johnson L, Choa R, Xu Y, Qiu J, Zhou Z . Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019; 178(4):933-948.e14. PMC: 6830508. DOI: 10.1016/j.cell.2019.07.019. View

Goel S, Bergholz J, Zhao J . Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022; 22(6):356-372. PMC: 9149100. DOI: 10.1038/s41568-022-00456-3. View

Watt A, Cejas P, DeCristo M, Metzger-Filho O, Lam E, Qiu X . CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat Cancer. 2021; 2(1):34-48. PMC: 8115221. DOI: 10.1038/s43018-020-00135-y. View

Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L . RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med. 2016; 22(8):933-9. DOI: 10.1038/nm.4118. View

10.

Benitez S, Cordero A, Santamaria P, Redondo-Pedraza J, Rocha A, Collado-Sole A . RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness. Dev Cell. 2021; 56(12):1727-1741.e7. PMC: 8221814. DOI: 10.1016/j.devcel.2021.04.022. View

11.

Attia Y, Shouman S, Salama S, Ivan C, Elsayed A, Amero P . Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer. Int J Mol Sci. 2020; 21(8). PMC: 7215326. DOI: 10.3390/ijms21082974. View

12.

Jones D, Nakashima T, Sanchez O, Kozieradzki I, Komarova S, Sarosi I . Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006; 440(7084):692-6. DOI: 10.1038/nature04524. View

13.

Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K . Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res. 2013; 32:62. PMC: 3847095. DOI: 10.1186/1756-9966-32-62. View

14.

Lypova N, Lanceta L, Gibson A, Vega S, Garza-Morales R, McMasters K . Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy. Cancers (Basel). 2019; 11(5). PMC: 6563125. DOI: 10.3390/cancers11050684. View

15.

Gomez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernandez-Jimenez E . Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nat Commun. 2020; 11(1):6335. PMC: 7728758. DOI: 10.1038/s41467-020-20138-8. View

16.

McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F . Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Front Oncol. 2019; 9:666. PMC: 6664013. DOI: 10.3389/fonc.2019.00666. View

17.

Platanitis E, Decker T . Regulatory Networks Involving STATs, IRFs, and NFκB in Inflammation. Front Immunol. 2018; 9:2542. PMC: 6242948. DOI: 10.3389/fimmu.2018.02542. View

18.

Beleut M, Rajaram R, Caikovski M, Ayyanan A, Germano D, Choi Y . Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A. 2010; 107(7):2989-94. PMC: 2840294. DOI: 10.1073/pnas.0915148107. View

19.

Asselin-Labat M, Vaillant F, Sheridan J, Pal B, Wu D, Simpson E . Control of mammary stem cell function by steroid hormone signalling. Nature. 2010; 465(7299):798-802. DOI: 10.1038/nature09027. View

20.

Sanz-Moreno A, Palomeras S, Pedersen K, Morancho B, Pascual T, Galvan P . RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. Breast Cancer Res. 2021; 23(1):42. PMC: 8008631. DOI: 10.1186/s13058-021-01390-2. View